Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons
- PMID: 20186036
- PMCID: PMC3800050
- DOI: 10.1097/QAD.0b013e3283333651
Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons
Abstract
Objective: To evaluate the relationship between regional body composition and liver disease (fibrosis or steatosis) in HIV/HCV co-infected individuals.
Methods: Whole body dual-energy X-ray absorptiometry (DXA) was performed in 173 HIV/HCV co-infected persons within 12 months of a liver biopsy. Significant fibrosis was defined as a METAVIR stage greater than 1. Steatosis was graded as: 0, none; 1, steatosis involving less than 5% of hepatocytes; 2, 5-29%; 3, 30-60%; 4 greater than 60%, and was defined as more than 0. Poisson regression with robust variance was used to estimate prevalence ratios of the outcome measures.
Results: The population was 62% male and 84% black with a median body mass index of 25.2 kg/m (interquartile range 22.5, 29.3 kg/m). No differences in regional body fat or fat distribution were observed in 42 patients with significant fibrosis compared to others with less fibrosis. However, the 77 individuals (45%) with steatosis had greater central fat than those without steatosis [prevalence ratio 1.04 per kg trunk fat; 95% confidence interval (CI) 1.04, 1.11], after adjusting for hepatic fibrosis (prevalence ratio 1.77; 95% CI 1.29, 2.42), uncontrolled HIV replication (viral load >400 copies/ml) (prevalence ratio 1.57; 95% CI 1.12, 2.22), age, sex, race and diabetes mellitus.
Conclusions: In HIV/HCV co-infected individuals, measures of regional body fat or fat distribution were not associated with hepatic fibrosis. In contrast, increased central adiposity by DXA, as well as concomitant fibrosis and uncontrolled HIV, were associated with hepatic steatosis. The extent to which weight loss and effective antiretroviral therapy can reduce the risk of steatosis deserves further investigation.
Figures
Similar articles
-
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.J Infect Dis. 2005 Dec 1;192(11):1943-9. doi: 10.1086/497608. Epub 2005 Nov 2. J Infect Dis. 2005. PMID: 16267765
-
Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy.J Acquir Immune Defic Syndr. 2010 Oct;55(2):228-31. doi: 10.1097/QAI.0b013e3181e1d963. J Acquir Immune Defic Syndr. 2010. PMID: 20512045 Free PMC article.
-
Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.J Hepatol. 2017 Oct;67(4):801-808. doi: 10.1016/j.jhep.2017.05.011. Epub 2017 May 18. J Hepatol. 2017. PMID: 28527666
-
Liver steatosis in HIV-infected patients.AIDS Rev. 2005 Oct-Dec;7(4):197-209. AIDS Rev. 2005. PMID: 16425960 Review.
-
[Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].Ann Ital Med Int. 2005 Jan-Mar;20(1):10-22. Ann Ital Med Int. 2005. PMID: 15859390 Review. Italian.
Cited by
-
BODY COMPOSITION CHANGES IN MEN WITH HIV/HCV COINFECTION, HIV MONOINFECTION, AND HCV MONOINFECTION.Acta Endocrinol (Buchar). 2022 Oct-Dec;18(4):442-451. doi: 10.4183/aeb.2022.442. Acta Endocrinol (Buchar). 2022. PMID: 37152870 Free PMC article.
-
Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot.J Antimicrob Chemother. 2019 Apr 1;74(4):1028-1034. doi: 10.1093/jac/dky551. J Antimicrob Chemother. 2019. PMID: 30668716 Free PMC article.
-
Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis.World J Hepatol. 2016 Jan 8;8(1):74-82. doi: 10.4254/wjh.v8.i1.74. World J Hepatol. 2016. PMID: 26783423 Free PMC article.
-
Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy.AIDS Res Hum Retroviruses. 2012 Jun;28(6):552-7. doi: 10.1089/aid.2011.0232. Epub 2012 Feb 2. AIDS Res Hum Retroviruses. 2012. PMID: 22145933 Free PMC article.
References
-
- Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641. - PubMed
-
- Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–569. - PubMed
-
- Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis. 2005;192:1943–1949. - PubMed
-
- Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS. 2006;20:525–531. - PubMed
-
- Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585–592. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 AA016893/AA/NIAAA NIH HHS/United States
- R01 DA011602/DA/NIDA NIH HHS/United States
- AA016893/AA/NIAAA NIH HHS/United States
- P30 AI094189/AI/NIAID NIH HHS/United States
- K24DA00432/DA/NIDA NIH HHS/United States
- K23AT002862/AT/NCCIH NIH HHS/United States
- HS07-809/HS/AHRQ HHS/United States
- DA-16065/DA/NIDA NIH HHS/United States
- U01 AI069918/AI/NIAID NIH HHS/United States
- M01RR-02719/RR/NCRR NIH HHS/United States
- R01 DA013806/DA/NIDA NIH HHS/United States
- K23 AT002862/AT/NCCIH NIH HHS/United States
- R37 DA013806/DA/NIDA NIH HHS/United States
- DA-11602/DA/NIDA NIH HHS/United States
- M01 RR002719/RR/NCRR NIH HHS/United States
- K24 DA000432/DA/NIDA NIH HHS/United States
- DA-13806/DA/NIDA NIH HHS/United States
- U01 DA036935/DA/NIDA NIH HHS/United States
- R21 AA015032/AA/NIAAA NIH HHS/United States
- R01 DA016065/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
